Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to the company?s previous intimation of 27 March 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
341.5 INR | +1.64% | +10.35% | +36.87% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 31 | Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
341.5 INR | +1.64% | +10.35% | 4.8B | ||
3.4 RON | -2.86% | -0.58% | 515M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.87% | 4.8B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.14% | 22.78B | |
-10.95% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution